Previous 10 | Next 10 |
Protagonist Therapeutics (PTGX) has priced its public offering of 4,761,904 common shares at $21.00/share, for expected gross proceeds of $100M.Underwriters' over-allotment is an additional 714,285 shares.Closing date is December 15.Shares down 2% after-hours.Previously: Protagonist...
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock NEWARK, Calif. , Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of ...
Protagonist Therapeutics (PTGX) has launched an underwritten public offering of $100M common shares.Underwriters have a 30-day option to purchase up to an additional 15% of the number of shares of its common stock. Source: Press Release For further details see: Protagonist therapeutics ...
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock NEWARK, Calif. , Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an ...
BMO Capital Markets is very positive on the update from Protagonist Therapeutics ([[PTGX]] +2.8%) at the ASH Conference. "We reiterate our Outperform rating on PTGX shares and increase our target price to $46 following our view of striking updated results from a Phase 2 trial evaluating PTG-3...
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories NEWARK, Calif. , Dec. 7, 2020 /PRNewswire/ --&...
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera NEWARK, Calif. , Dec. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) toda...
The FDA grants Fast Track status to Protagonist Therapeutics' (PTGX) PTG-300 for the treatment of polycythemia vera, a type of rare blood disorder characterized by the excessive production of red blood cells.Fast Track provides for more frequent interaction with the FDA review ...
Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera NEWARK, Calif. , Dec. 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) to...
Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...